Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Switzerland / NCT06998251
Recruiting Observational

In-depth Analysis of the Immune Responses in the Upper Respiratory Tract in Older Adults Infected or Colonized With Streptococcus Pneumoniae (Spn)

NCT06998251 · tracked via the Priya Life Science Switzerland tracker
Sponsor
University Hospital, Geneva
Phase
Observational
Started
2024-12-03
Last updated
2025-05-31

Condition(s) studied

Pneumococcal InfectionsRespiratory Syncytial Virus (RSV) InfectionInfluenza Infection

Study summary

The NoseSpn-Elderly study aims at characterizing the immune response in the upper respiratory tract in adults aged 60 and over diagnosed with a pneumonia due to a Streptococcus pneumoniae (Spn) infection. The immune response during the acute phase of the infection and after recovery will be compared to the immune response of asymptomatic Spn carriers as well as to the immune response of patients diagnosed with a viral respiratory infection (flu or respiratory syncytial virus (RSV)).

The primary objective of this observational study is to quantify the inflammatory response in the nasal cavity and to correlate it with bacterial/viral load and with clinical parameters. The study also aims to compare the inflammatory response measured in the nose to that measured in the blood.

Participants will have two study visits including a blood draw, several nasal samplings (nasal lining fluid and nasal cells) and a saliva sampling, one within 72 hours of their hospital admission and another one month later. Nasal lining fluid and saliva will be obtained every two or three days until discharge from the hospital or resolution of symptoms. During those visits, questions regarding symptoms will be asked.

Eligibility

Sex
ALL
Min age
60 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion criteria: * Aged 60-85 years * Able to provide informed consent either independently or by a legal representative * Group 1 (Spn pneumonia patients): clinical and/or radiological signs of pneumonia * Group 1 (Spn pneumonia patients): positive Spn urinary antigen and/or blood culture and/or positive sputum test. * Group 2 (viral respiratory infection patients): clinical signs of a respiratory infection * Group 2 (viral respiratory infection patients): positive test for influenza or RSV * Group 3 (asymptomatic Spn-carriers): healthy without clinical signs of infection and no lower respiratory symptoms within the last month. Exclusion criteria: * Immunosuppression, * Use of inhalation and/or nasal steroids the last month * Intubation or under invasive mechanical ventilation * Long-term antibiotic treatment prior to disease onset

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Geneva University Hospitals Geneva Switzerland Recruiting

More University Hospital, Geneva trials in Switzerland

Radiosurgery Induced Ototoxicity in Patients Treated for a Vestibular Schwannoma Recruiting
In-depth Analysis of the Immune Responses in the Upper Respiratory Tract of Influenza-infected Children Recruiting
ONE-SHOT Trial - Ultra-hypofractionated Single-dose SBRT for Prostate Cancer Recruiting
Association Between Female Hormonal Profile and Wound Healing Starting soon
Genetic Risks for Childhood Cancer Complications in Switzerland Recruiting

Other trials for the same condition

In-depth Analysis of the Immune Responses in the Upper Respiratory Tract of Influenza-infected Children Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06998251 on ClinicalTrials.gov ↗ ← All trials in Switzerland